Pseudotropine

Pseudotropine

SCHEMBL64824

CN1[C@@H]2CC[C@H]1CC(O)C2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 1.00
CYP2C9 P11712 1/20 1.00
CHRM3 P20309 6/20 0.42
CHRM2 P08172 5/20 0.42
CHRM1 P11229 5/20 0.42
TDP1 Q9NUW8 1/20 0.41
SLC6A2 P23975 2/20 0.38
SLC6A3 Q01959 2/20 0.38
OPRL1 P41146 1/20 0.37
HTR3E A5X5Y0 2/20 0.36
HTR3B O95264 2/20 0.36
HTR3A P46098 2/20 0.36
HTR3D Q70Z44 2/20 0.36
HTR3C Q8WXA8 2/20 0.36
CHRNA7 P36544 1/20 0.36
CHRM4 P08173 2/20 0.35
CHRM5 P08912 1/20 0.35
ADRA2A P08913 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2B P18089 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pseudotropine SCHEMBL6944859 1.00 LMNA (1.00) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL38978 1.00 LMNA (1.00) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL21563309 1.00 LMNA (1.00) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL100196 1.00 LMNA (1.00) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL31078606 1.00 LMNA (1.00) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL2442824 1.00 LMNA (1.00) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL745726 1.00 LMNA (1.00) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL228981 0.97 LMNA (0.94) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL7296801 0.97 LMNA (0.94) LMNACYP2C9CHRM3CHRM2CHRM1
Pseudotropine SCHEMBL7296808 0.97 LMNA (0.94) LMNACYP2C9CHRM3CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4607278-A1 CHEMICALLY-AMPLIFIED POSITIVE PHOTORESIST COMPOSITION FOR PATTERN PROFILE IMPROVEMENT AND ETCH RESISTANCE ENHANCEMENT Ycchem Co., Ltd. (KR) 2025-08-27 EP claimed
US-20250199405-A1 CHEMICALLY-AMPLIFIED POSITIVE PHOTORESIST COMPOSITION FOR PATTERN PROFILE IMPROVEMENT AND ETCH RESISTANCE ENHANCEMENT YCCHEM CO., LTD. (KR) 2025-06-19 US claimed
CN-119998727-A Chemically amplified positive resist composition for improving pattern profile and enhancing etch resistance YC化学制品株式会社 2025-05-13 CN claimed
WO-2024085293-A1 CHEMICALLY-AMPLIFIED POSITIVE PHOTORESIST COMPOSITION FOR PATTERN PROFILE IMPROVEMENT AND ETCH RESISTANCE ENHANCEMENT 영창케미칼 주식회사 2024-04-25 WO claimed
US-10000502-B2 Substituted thiohydantoin derivatives as androgen receptor antagonists JANSSEN PHARMACEUTICA NV (BE) 2018-06-19 US claimed
US-20170233401-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS JANSSEN PHARMACEUTICA NV (BE) 2017-08-17 US claimed
US-7727707-B2 Barrier film material and pattern formation method using the same PANASONIC CORPORATION (JP) 2010-06-01 US claimed
US-7135273-B2 Pattern formation method MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. (JP) 2006-11-14 US claimed
US-20060127812-A1 Barrier film material and pattern formation method using the same MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. 2006-06-15 US claimed
EP-1669804-A2 Barrier film material and pattern formation method using the same Matsushita Electric Industries Co., Ltd. (JP) 2006-06-14 EP claimed
CN-1574218-A Pattern formation method MATSUSHITA ELECTRIC INDUSTRIAL CO LTD (JP) 2005-02-02 CN claimed
US-20040259040-A1 Pattern formation method MATSUSHITA ELECTRIC INDUSTRIAL CO., LTD. 2004-12-23 US claimed
EP-0294292-B1 Derivative of benzo[b]thiophene-7-carboxylic acid, process for its preparation and pharmaceutical compositions containing it ADIR ET COMPAGNIE (FR) 1991-10-09 EP claimed
US-12630742-B2 Polishing composition using polishing particles containing basic substance and having high water affinity NISSAN CHEMICAL CORPORATION (JP) 2026-05-19 US disclosed
US-20260083724-A1 COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN GEORGETOWN UNIVERSITY (US) 2026-03-26 US disclosed
US-12583973-B2 Polyimide-based polymer, positive photosensitive resin composition, negative photosensitive resin composition, patterning method, method for forming cured film, interlayer insulating film, surface protective film, and electronic component SHIN-ETSU CHEMICAL CO., LTD. (JP) 2026-03-24 US disclosed
US-4698217-A Crystalline silicate ZSM-58 and process for its preparation using a methyltropinium cation MOBIL OIL CORPORATION (US) 1987-10-06 US disclosed
US-4665264-A ZEOLITE ZSM-58, GASOLINE MOBIL OIL CORPORATION (US) 1987-05-12 US disclosed
EP-0193282-A2 A crystalline silicate and method of its synthesis MOBIL OIL CORPORATION (US) 1986-09-03 EP disclosed
US-4197237-A Antibodies to nitrogen derivatives of benzoyl ecgonine antigenic conjugates thereof SYVA COMPANY (US) 1980-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233401-A1 SUBSTITUTED THIOHYDANTOIN DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS AR, SHBG, NR5A1 LMNA 4294/4885CYP2C9 595/4885CHRM3 1582/4885
US-10000502-B2 Substituted thiohydantoin derivatives as androgen receptor antagonists AR, SHBG, NR5A1 LMNA 4294/4885CYP2C9 595/4885CHRM3 1582/4885
US-12630742-B2 Polishing composition using polishing particles containing basic substance and having high water affinity POLR1A, PRMT1, SRRM2 LMNA 978/4885CYP2C9 4751/4885CHRM3 254/4885
US-20260083724-A1 COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN PAX3, FOXO1, PAXBP1 LMNA 1864/4885CYP2C9 4570/4885CHRM3 2989/4885
US-12583973-B2 Polyimide-based polymer, positive photosensitive resin composition, negative photosensitive resin composition, patterning method, method for forming cured film, interlayer insulating film, surface protective film, and electronic component PRDM9, ARCN1, PUF60 LMNA 2609/4885CYP2C9 3892/4885CHRM3 2184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.